Why Cholesterol Changes During Menopause—and What Women Should Know
Many women enter their 40s and 50s doing the same things they have always done—eating well, exercising and maintaining a healthy weight—only to discover that their cholesterol has suddenly increased.
This is not always the result of poor lifestyle choices. The hormonal changes of perimenopause and menopause can directly affect how the liver processes cholesterol, how fat is distributed and how efficiently the body responds to insulin.
Understanding these changes allows women to address cardiovascular risk early instead of dismissing an abnormal lipid panel as “just part of getting older.”
Why does cholesterol rise during menopause?
Estrogen influences several aspects of lipid metabolism. It helps support LDL-receptor activity in the liver, allowing the body to remove LDL cholesterol from circulation more efficiently. Estrogen also affects insulin sensitivity, inflammation, blood-vessel function and where the body stores fat.
As ovarian estrogen production becomes less consistent during perimenopause and eventually declines after menopause, women may experience:
Higher LDL cholesterol
Higher total cholesterol
Higher non-HDL cholesterol
Increased apolipoprotein B, or ApoB
Higher triglycerides
More small, dense LDL particles
An increase in abdominal and visceral fat
Greater insulin resistance
Possible increases in lipoprotein(a), or Lp(a)
Importantly, these changes can begin several years before the final menstrual period. Research tracking women through the menopause transition found that total cholesterol, LDL cholesterol and ApoB may begin rising approximately five years before menopause—not simply after menstruation stops.
The American Heart Association recognizes the menopause transition as an important period for accelerated cardiovascular risk assessment and prevention. Longitudinal studies, including the Study of Women’s Health Across the Nation, have demonstrated that increases in LDL and ApoB are related to menopause itself and cannot be explained entirely by chronological aging or weight gain.
LDL cholesterol is only part of the picture
A traditional lipid panel includes total cholesterol, LDL, HDL and triglycerides. These values remain useful, but they do not always tell the entire story.
ApoB
ApoB represents the number of potentially atherogenic particles circulating in the bloodstream. Each LDL, VLDL, IDL and Lp(a) particle carries one ApoB molecule.
This means that ApoB can provide a better estimate of the number of cholesterol-containing particles capable of entering the artery wall. A person can have an apparently acceptable LDL cholesterol level but still have an elevated ApoB and a high number of atherogenic particles.
ApoB is particularly helpful when triglycerides are elevated or when a woman has insulin resistance, diabetes, metabolic syndrome or discordance between LDL and non-HDL cholesterol.
Lipoprotein(a)
Lipoprotein(a), usually written as Lp(a), is a genetically influenced cholesterol particle associated with heart attack, stroke and aortic-valve disease.
Lp(a) is largely inherited and is not meaningfully lowered through diet or exercise. Levels may rise modestly following menopause, although researchers are still determining how much of this change results from hormonal loss versus aging.
Because most people with elevated Lp(a) have no symptoms, obtaining the test at least once in adulthood can identify inherited risk that would otherwise remain hidden.
Non-HDL cholesterol
Non-HDL cholesterol is calculated by subtracting HDL from total cholesterol. It captures all ApoB-containing cholesterol particles and can be especially useful when triglycerides are elevated.
Is HDL always protective?
HDL is commonly called “good cholesterol,” but the menopause research reveals a more complicated story.
HDL cholesterol may remain stable or even increase during menopause. However, a higher HDL number does not necessarily mean that the HDL particles are functioning normally.
Research from the SWAN study suggests that HDL composition, particle size and cholesterol-removal capacity change during the menopause transition. In some postmenopausal women, very high HDL may no longer have the same protective association observed before menopause.
The goal should therefore not be to increase HDL at all costs. LDL, non-HDL cholesterol, ApoB, triglycerides, blood pressure, glucose control, smoking history and overall cardiovascular risk provide more actionable information.
How does menopause hormone therapy affect cholesterol?
Menopause hormone therapy can improve some lipid measurements, but its effects depend on the dose, route and specific combination of hormones.
A systematic review and meta-analysis of 73 randomized trials found that menopausal hormone therapy generally reduced total cholesterol, LDL cholesterol and Lp(a). However, changes in triglycerides differed significantly between oral and transdermal estrogen.
Oral estrogen
Oral estrogen passes through the liver before entering systemic circulation. This “first-pass” hepatic effect generally:
Lowers LDL cholesterol more noticeably
Raises HDL cholesterol
Lowers Lp(a)
Can increase triglycerides
Increases the production of certain clotting and inflammatory proteins
For a woman with elevated triglycerides, insulin resistance, gallbladder concerns or increased risk for blood clots, oral estrogen may not be the preferred route.
Transdermal estradiol
Transdermal estradiol, delivered through a patch, gel or spray, bypasses first-pass liver metabolism. It generally:
Produces a modest reduction or neutral effect on LDL
Has little effect on HDL
Is neutral or potentially favorable for triglycerides
Has less effect on clotting proteins than oral estrogen
For women with high triglycerides or cardiometabolic risk factors, transdermal estradiol is often the more metabolically neutral option.
Does progesterone affect cholesterol?
The type of progestogen also matters. Micronized progesterone generally has a neutral effect on lipids and is less likely to interfere with estrogen’s favorable lipid effects.
Some synthetic progestins—particularly those with greater androgenic activity—may partially reduce the increase in HDL or other lipid benefits associated with estrogen.
Better cholesterol numbers do not automatically mean fewer heart attacks
This is one of the most important distinctions in menopause medicine.
Hormone therapy can improve several laboratory markers, but improving a lipid panel is not the same as proving that a treatment prevents heart attacks or strokes.
The Women’s Health Initiative demonstrated that starting oral conjugated estrogen with medroxyprogesterone in an older population did not prevent cardiovascular disease and increased certain risks. The average participant was approximately 63 years old, and many were more than a decade beyond menopause.
Later research led to the “timing hypothesis”: hormone therapy may have a more favorable cardiovascular profile when started in healthy, symptomatic women who are younger than 60 or within 10 years of menopause, before significant atherosclerosis has developed.
In the ELITE randomized trial, oral estradiol slowed the progression of carotid-artery thickening when started within six years of menopause, but not when started 10 or more years after menopause. The KEEPS trial, however, did not demonstrate significantly less progression of coronary calcium or carotid thickening with lower-dose hormone therapy.
Taken together, these studies suggest that timing, age, baseline health, formulation and route all matter—but hormone therapy should not be prescribed solely to lower cholesterol or prevent cardiovascular disease.
The Endocrine Society recommends using established lipid-lowering therapy, such as statins when clinically indicated, rather than using hormone therapy as cholesterol treatment.
Should women with high cholesterol avoid estrogen?
Not necessarily.
Elevated cholesterol alone does not automatically exclude a woman from receiving menopause hormone therapy. The decision should consider her complete cardiovascular and medical profile, including:
Age and time since menopause
LDL, non-HDL cholesterol and ApoB
Triglyceride level
Lp(a)
Blood pressure
Diabetes or insulin resistance
Smoking
Personal or family history of cardiovascular disease
Previous blood clots or stroke
Migraine history
Liver and gallbladder health
Breast-cancer risk
Type, dose and route of hormone therapy
For many healthy women with bothersome menopause symptoms who are younger than 60 or within 10 years of menopause, the benefits of appropriately selected hormone therapy may outweigh the risks. Transdermal estradiol is often favored when triglycerides or vascular risk factors are present.
What testing should women consider during perimenopause?
A thoughtful cardiovascular assessment may include:
Fasting or nonfasting lipid panel
ApoB
Lp(a), generally measured at least once
Hemoglobin A1c and fasting glucose
Blood pressure
Thyroid testing
Liver and kidney function
Family history of early heart disease
Assessment for metabolic syndrome
Coronary-artery calcium scoring when appropriate for an uncertain treatment decision
Thyroid dysfunction, diabetes, kidney disease, liver disease, genetics, medications, alcohol intake and dietary changes can also affect cholesterol. An increase should not automatically be attributed to menopause without considering these additional factors.
How can cholesterol be improved during menopause?
The most effective strategy is individualized and may include:
Resistance training to preserve muscle and improve insulin sensitivity
Regular aerobic exercise
Adequate protein and soluble fiber
A Mediterranean-style eating pattern
Replacing saturated fats with unsaturated fats
Limiting smoking and excessive alcohol
Improving sleep and treating sleep apnea when present
Managing blood pressure and blood sugar
Treating hypothyroidism or other secondary causes
Statin or non-statin medication when indicated
Appropriately selected menopause hormone therapy for menopausal symptoms—not as a substitute for lipid treatment
The bottom line
Menopause is a metabolic transition, not simply the end of menstrual periods. LDL cholesterol, ApoB, triglycerides and visceral fat can increase even when a woman’s diet, exercise habits and weight have not meaningfully changed.
Estrogen therapy may improve certain lipid measurements, but the effects differ between oral and transdermal treatment. Improved cholesterol numbers also do not guarantee cardiovascular protection.
The most effective approach is to evaluate the complete picture: symptoms, hormone-therapy goals, cholesterol particles, metabolic health, genetics and overall cardiovascular risk.
At Morrell Wellness, we believe women deserve more than a quick look at total cholesterol. A personalized menopause evaluation can help identify what is changing, determine which laboratory markers matter and create an evidence-based plan for hormone and long-term metabolic health.
Selected Medical References
American Heart Association Scientific Statement: Menopause Transition and Cardiovascular Disease Risk (https://www.ahajournals.org/doi/10.1161/CIR.0000000000000912)
SWAN: Cardiovascular Risk-Factor Changes During the Menopause Transition (https://www.jacc.org/doi/10.1016/j.jacc.2009.10.009)
Effects of Menopause Hormone Therapy on Lipids: Systematic Review and Meta-Analysis of 73 Trials (https://pmc.ncbi.nlm.nih.gov/articles/PMC9039020/)
HDL Particle and Function Changes During Menopause (https://pmc.ncbi.nlm.nih.gov/articles/PMC8105263/)
The Menopause Society 2022 Hormone Therapy Position Statement (https://pubmed.ncbi.nlm.nih.gov/35797481/)
Endocrine Society Clinical Practice Guideline: Lipid Management in Endocrine Disorders (https://www.endocrine.org/clinical-practice-guidelines/lipid-management-guideline)
ELITE Trial: Early Versus Late Postmenopausal Estradiol and Atherosclerosis (https://www.nejm.org/doi/full/10.1056/NEJMoa1505241)
This article is intended for education and does not replace individualized medical evaluation or treatment.
